IL17A and relapsing-remitting multiple sclerosis: IL-17A in combination with IL-6 has been also described to promote the breakdown of BBB in RRMS patients [71] by altering the expression of adhesion molecules on endothelial cells [72,73] and favoring the depolymerization of the actin cytoskeleton near the tight junctions [74].